Sarcopenia and loss of muscle mass in patients with lung cancer undergoing chemotherapy treatment: a systematic review and meta-analysis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• A Jemal LT, Soerjomataram I, Bray F. The cancer atlas. 3 ed. USA: American Cancer Society, Inc; 2019.
   Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017; 151(1):193–203.
   PubMed Web of Science ®Google Scholar
• Larry Jameson ASF J, Kasper DL, et. al. Harrison’s principles of internal medicine. 20 ed.: New York: Cenveo Publisher Services; 2018.
   Google Scholar
• Blanchon F, Grivaux M, Asselain B, et al. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol. 2006;7(10):829–836.
   PubMed Web of Science ®Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020; 383(7):640–649.
   PubMed Web of Science ®Google Scholar
• OECDiLibrary. Incidence, survival and mortality for lung cancer [cited 2022. 24. february]. Available from: https://www.oecd-ilibrary.org/sites/547f405e-en/index.html?itemId=/content/component/547f405e-en.
   Google Scholar
• Santilli V, Bernetti A, Mangone M, et al. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014; 11(3):177–180.
   PubMedGoogle Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019; 393(10191):2636–2646.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010; 1(2):129–133.
   PubMed Web of Science ®Google Scholar
• Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019; 8(1):86–101.
   PubMed Web of Science ®Google Scholar
• Wilson D, Jackson T, Sapey E, et al. Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev. 2017; 36:1–10.
   PubMed Web of Science ®Google Scholar
• Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006; 61(10):1059–1064.
   PubMed Web of Science ®Google Scholar
• Rier HN, Jager A, Sleijfer S, et al. The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature. Oncologist. 2016; 21(11):1396–1409.
   PubMed Web of Science ®Google Scholar
• Simonsen C, Kristensen TS, Sundberg A, et al. Assessment of sarcopenia in patients with upper gastrointestinal tumors: prevalence and agreement between computed tomography and dual-energy x-ray absorptiometry. Clin Nutr. 2021;40(5):2809–2816.
   PubMed Web of Science ®Google Scholar
• Atlan P, Bayar MA, Lanoy E, et al. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. Support Care Cancer. 2017;25(11):3365–3373.
   PubMed Web of Science ®Google Scholar
• Kodera Y. More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of care. Gastric Cancer. 2015;18(2):203–204.
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009; 34(2):380–386.
   PubMed Web of Science ®Google Scholar
• Titz C, Hummler S, Schmidt ME, et al. Exercise behavior and physical fitness in patients with advanced lung cancer. Support Care Cancer. 2018; 26(8):2725–2736.
   PubMed Web of Science ®Google Scholar
• Coups EJ, Park BJ, Feinstein MB, et al. Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life. Cancer Epidemiol Biomarkers Prev. 2009; 18(2):664–672.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Hanaoka J, Ohshio Y, et al. Does sarcopenia affect postoperative short- and long-term outcomes in patients with lung cancer?-a systematic review and meta-analysis. J Thorac Dis. 2021;13(3):1358–1369.
   PubMed Web of Science ®Google Scholar
• Nipp RD, Fuchs G, El-Jawahri A, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist. 2018; 23(1):97–104.
   PubMed Web of Science ®Google Scholar
• Simonsen C, de Heer P, Bjerre ED, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology: a meta-analysis. Ann Surg. 2018; 268(1):58–69.
   PubMed Web of Science ®Google Scholar
• Pamoukdjian F, Bouillet T, Lévy V, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr. 2018;37(4):1101–1113.
   PubMed Web of Science ®Google Scholar
• Yang M, Shen Y, Tan L, et al. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest. 2019;156(1):101–111.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.
   PubMed Web of Science ®Google Scholar
• McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276–282.
   PubMed Web of Science ®Google Scholar
• NHLBI. NIH. Study quality assessment tools. [Internet]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82(4):591–605.
   PubMed Web of Science ®Google Scholar
• PmfR2021. Available from: https://cran.r-project.org/web/packages/meta/meta.pdf.
   Google Scholar
• Nattenmüller J, Wochner R, Muley T, et al. Prognostic impact of CT-Quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients. PLOS One. 2017;12(1):e0169136.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Palumbo P, Porzio G, et al. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer. 2018;9(12):1623–1630.
   PubMed Web of Science ®Google Scholar
• Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015; 54(3):340–348.
   PubMed Web of Science ®Google Scholar
• Petrova MP, Donev IS, Radanova MA, et al. Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clin Exp Immunol. 2020; 202(3):353–362.
   PubMed Web of Science ®Google Scholar
• Nishioka N, Uchino J, Hirai S, et al. Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. J Clin Med. 2019;8(4):450.
   Web of Science ®Google Scholar
• Kimura M, Naito T, Kenmotsu H, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015;23(6):1699–1708.
   PubMed Web of Science ®Google Scholar
• Goncalves MD, Taylor S, Halpenny DF, et al. Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clin Radiol. 2018;73(5):505.e1–505–e8.
   PubMed Web of Science ®Google Scholar
• Kakinuma K, Tsuruoka H, Morikawa K, et al. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer. Thorac Cancer. 2018; 9(1):99–104.
   PubMed Web of Science ®Google Scholar
• Kazemi-Bajestani SMR, Becher H, Butts C, et al. Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. J Cachexia Sarcopenia Muscle. 2019;10(5):1070–1082.
   PubMed Web of Science ®Google Scholar
• Naito T, Okayama T, Aoyama T, et al. Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 2017;17(1):571.
   PubMedGoogle Scholar
• Jang MK, Park C, Hong S, et al. Skeletal muscle mass change during chemotherapy: a systematic review and meta-analysis. Anticancer Res. 2020;40(5):2409–2418.
   PubMed Web of Science ®Google Scholar
• Hansen TTD, Omland LH, von Heymann A, et al. Development of sarcopenia in patients with bladder cancer: a systematic review. Semin Oncol Nurs. 2021;37(1):151108.
   PubMed Web of Science ®Google Scholar
• Daly LE, Nb ÉB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):315–325.
   PubMed Web of Science ®Google Scholar
• van der Zanden V, van Soolingen NJ, Viddeleer AR, et al. Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. Eur J Surg Oncol. 2022;48(4):896–902.
   PubMed Web of Science ®Google Scholar
• Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19(5):1336–1343.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1335–1343.
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–799.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495.
   PubMed Web of Science ®Google Scholar
• Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90(10):1905–1911.
   PubMed Web of Science ®Google Scholar
• Van Gammeren D, Damrauer JS, Jackman RW, et al. The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy. Faseb J. 2009;23(2):362–370.
   PubMed Web of Science ®Google Scholar
• Gérard S, Bréchemier D, Lefort A, et al. Body composition and anti-neoplastic treatment in adult and older subjects – A systematic review. J Nutr Health Aging. 2016;20(8):878–888.
   PubMed Web of Science ®Google Scholar
• Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer. 2003;98(9):1786–1801.
   PubMed Web of Science ®Google Scholar
• Love RR, Leventhal H, Easterling DV, et al. Side effects and emotional distress during cancer chemotherapy. Cancer. 1989;63(3):604–612.
   PubMed Web of Science ®Google Scholar
• Carlson LE, Zelinski EL, Toivonen KI, et al. Prevalence of psychosocial distress in cancer patients across 55 North American cancer centers. J Psychosoc Oncol. 2019;37(1):5–21.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu X, Tong F, et al. Lung cancer distress: screening thermometer meta-analysis. BMJ Support Palliat Care. 2022;0:1–9.
   Google Scholar
• Geerse OP, Brandenbarg D, Kerstjens HAM, et al. The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer. Lung Cancer. 2019;130:101–107.
   PubMed Web of Science ®Google Scholar
• Linares-Moya M, Rodríguez-Torres J, Heredia-Ciuró A, et al. Psychological distress prior to surgery is related to symptom burden and health status in lung cancer survivors. Support Care Cancer. 2022;30(2):1579–1586.
   PubMed Web of Science ®Google Scholar
• Zhang JM, Zhang MR, Yang CH, et al. The meaning of life according to patients with advanced lung cancer: a qualitative study. Int J Qual Stud Health Well-being. 2022;17(1):2028348.
   PubMed Web of Science ®Google Scholar
• Schoenau MN, Hansen M, Ulvestad S, et al. The lived experiences, perceptions, and considerations of patients after operable lung cancer concerning nonparticipation in a randomized clinical rehabilitation trial. Qual Health Res. 2020;30(5):760–771.
   PubMed Web of Science ®Google Scholar
• Dunne RF, Loh KP, Williams GR, et al. Cachexia and sarcopenia in older adults with cancer: a comprehensive review. Cancers. 2019;11(12):1861.
   Web of Science ®Google Scholar
• Cao A, Ferrucci LM, Caan BJ, et al. Effect of exercise on sarcopenia among cancer survivors: a systematic review. Cancers. 2022;14(3):786.
   Web of Science ®Google Scholar
• Edvardsen E, Skjønsberg OH, Holme I, et al. High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax. 2015;70(3):244–250.
   PubMed Web of Science ®Google Scholar
• Christensen JF, Jones LW, Tolver A, et al. Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial. Br J Cancer. 2014; 111(1):8–16.
   PubMed Web of Science ®Google Scholar
• Quist M, Langer SW, Lillelund C, et al. Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: a randomized clinical trial. Lung Cancer. 2020;145:76–82.
   PubMed Web of Science ®Google Scholar
• Kasymjanova G, Correa JA, Kreisman H, et al. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(5):602–607.
   PubMed Web of Science ®Google Scholar
• Williams GR, Dunne RF, Giri S, et al. Sarcopenia in the older adult with cancer. J Clin Oncol. 2021; 39(19):2068–2078.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee SM, Jeung HC, et al. The effect of nutrition intervention with oral nutritional supplements on pancreatic and bile duct cancer patients undergoing chemotherapy. Nutrients. 2019;11(5):1145.
   Web of Science ®Google Scholar
• Jang MK, Park C, Tussing-Humphreys L, et al. The effectiveness of sarcopenia interventions for cancer patients receiving chemotherapy: a systematic review and meta-analysis. Cancer Nurs. 2021;46(2):81–90.
   Web of Science ®Google Scholar
• Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(5):778–788.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–1547.
   Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–635.
   Google Scholar